Unlocking the potential of established products: toward new incentives rewarding innovation in Europe.
Ontology highlight
ABSTRACT: Background: Many established products (EPs - marketed for eight years or more) are widely used off-label despite little evidence on benefit-risk ratio. This exposes patients to risks related to safety and lack of efficacy, and healthcare providers to liability. Introducing new indications for EPs may represent a high societal value; however, manufacturers rarely invest in R&D for EPs. The objective of this research was to describe incentives and disincentives for developing new indications for EPs in Europe and to investigate consequences of current policies. Methods: Targeted literature search and expert panel meetings. Results: Within the current European-level and national-level regulatory framework there are limited incentives for development of new indications wit
SUBMITTER: Nayroles G
PROVIDER: S-EPMC5508393 | biostudies-literature | 2017
REPOSITORIES: biostudies-literature
ACCESS DATA